



Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.4. Antihepatitis medicines > 6.4.4.2. Medicines for hepatitis C > 6.4.4.2.1. Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

EMLc

ATC codes: J05AP08

<b>Indication</b>	Chronic hepatitis C <span style="background-color: #00AEEF; color: white; padding: 2px 5px;">ICD11 code: 1E91.1</span>
<b>INN</b>	Sofosbuvir
<b>Medicine type</b>	Chemical agent
<b>List type</b>	Core (EML) (EMLc)
<b>Additional notes</b>	Pangenotypic when used in combination with daclatasvir or ravidasvir.
<b>Formulations</b>	Oral > Solid > tablet: 200 mg ; 400 mg
<b>EML status history</b>	First added in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2021 (TRS 1035) Changed in 2023 (TRS 1049)
<b>Sex</b>	All
<b>Age</b>	Also recommended for children
<b>Therapeutic alternatives</b>	Medicines within the same pharmacological class can be used
<b>Therapeutic alternatives limitations</b>	Pangenotypic direct-acting antiviral combinations
<b>Therapeutic alternatives limitations for EMLc</b>	Pangenotypic direct-acting antiviral combinations
<b>Patent information</b>	Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a>
<b>Wikipedia</b>	<a href="#">Sofosbuvir</a>
<b>DrugBank</b>	<a href="#">Sofosbuvir</a>

### Summary of evidence and Expert Committee recommendations

The note associated with the listing of sofosbuvir was updated following the recommendation to include ravidasvir on the EML.

